Adam Feuerstein ✡️ — Take a look at the $EYPT stream on X since the lawsuit against $OCUL was filed. Nonstop posts with AI generated images from dozens of fake accounts.
This can’t be a coincidence.…↗
Adam Feuerstein ✡️ — @toplvl_excutive @houmanhemmati Agreed. As I said earlier, $OCUL modeled Axpaxli durability very well, but not so with low dose Eylea. The risk of this unconventional study design…↗
Adam Feuerstein ✡️ — $OCUL insta-take: Bulls and bears both have something to chew on, highlight.
Axpaxli durability almost exactly what $OCUL predicted, but they guessed wrong on Eylea.
Fluid cont…↗
Feb 17
Adam Feuerstein ✡️ — $OCUL SOL-1 readout is here! Top-line results:
Rescue-free rates: Axpaxli 74% at nine months, 66% at one year vs Eylea low dose 56% and 44%. Difference (benefit) 18 percentage poi…
January 2026 · 3 mentions
Jan 31
Adam Feuerstein ✡️ — @BiotechPort Can you define $OCUL fail?” No stat sig difference in maintenance of visual acuity at 9 months? Or the benefit is too marginal?↗
Jan 15
Adam Feuerstein ✡️ — Is there a single person feeding La Lettre fake biotech takeover tips, or is this a group effort? The stock manipulation is brazen.
First, we learn all the $ABVX $LLY French Mini…↗
Jan 8
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter:
Ocular Therapeutix $OCUL faces looming test of a more durable eye treatment. A preview of the Axpaxli SOL-1 clinical trial readout expec…↗
Adam Feuerstein ✡️ — @firebutworking $OCUL BCVA data from SOL-1 equally important bc it translates more to how wet AMD is treated.↗
Feb 5
Adam Feuerstein ✡️ — @NicholasChoupak 100% agree with you. It's a very odd strategy for $EYPT to take. Duker should be cheering for $OCUL, not trash talking.↗
Feb 5
Adam Feuerstein ✡️ — I received a strongly worded statement from $OCUL
“The rumors that are circulating alleging that we have seen the unmasked results from the SOL-1 trial or have knowledge that the…↗
Feb 5
Adam Feuerstein ✡️ — A rival goes after Ocular Therapeutix $OCUL on eve of pivotal readout on eye treatment
Eyepoint Pharma $EYPT CEO said to have trash-talked Ocular’s drug at a recent investor confe…↗
Feb 5
Adam Feuerstein ✡️ — $OCUL earnings posted this morning, plus an Axpaxli SOL-1 trial update.
Topline results will be announced in the "second half of February," the company said today. The study will…↗